RNF31 induces paclitaxel resistance by sustaining ALYREF cytoplasmic–nuclear shuttling in human triple‐negative breast cancer
Clinical and Translational Medicine · 2025
DOI: 10.1002/ctm2.70203 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Shumei Huang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-se…. Hauptthemen laut MEDLINE: Paclitaxel, Triple Negative Breast Neoplasms, Drug Resistance, Neoplasm, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Background
Resistance to paclitaxel‐based chemotherapy is the major obstacle in triple‐negative breast cancer (TNBC) treatment. However, overcoming paclitaxel resistance remains an unsolved problem. The present study aimed to determine whether paclitaxel treatment impairs Aly/REF export factor (ALYREF) cytoplasmic–nuclear shuttling, its mechanism, and the role of ubiquitinated ALYREF in paclitaxel resistance.
Methods
The subcellular proportion of ALYREF was detected in samples from patients with TNBC using immunohistochemistry to analyze the relationship between ALYREF distribution and paclitaxel response. Cell viability assays, immunofluorescence assays, quantitative real‐time reverse transcription PCR assays, western blotting, and terminal deoxynucleotidyl transferase nick‐end‐labelling assays were conducted to measure the biological function of the subcellular proportion of ALYREF and E3 ligase ring finger protein 31 (RNF31) on paclitaxel sensitivity in TNBC. The synergistic effects of an RNF31 inhibitor plus paclitaxel on TNBC were evaluated. Cox regression models were adopted to assess the prognostic role of RNF31 in TNBC.
Results
Herein, we showed that regulation of ALYREF cytoplasmic–nuclear shuttling is associated with the paclitaxel response in TNBC. In paclitaxel‐sensitive TNBC, ALYREF was trapped in the cytoplasm by paclitaxel, while in paclitaxel‐resistant TNBC, ALYREF was efficiently transported into the nucleus to exert its function, allowing the export of the mRNAs encoding paclitaxel‐resistance‐related factors, including tubulin beta 3 class III (TUBB3), stathmin 1 (STMN1), and microtubule‐associated protein Tau (TAU), ultimately inducing paclitaxel resistance in TNBC. Mechanistically, we found that RNF31 interacts with and ubiquitinates ALYREF, which facilitates ALYREF nuclear transportation via importin 13 (IPO13) under paclitaxel treatment. Notably, the RNF31 inhibitor and paclitaxel synergistically repressed tumour growth in vivo and in TNBC patient‐derived organoids. In addition, analysis of patients with TNBC showed that elevated RNF31 levels correlated with poor prognosis.
Conclusion
These data indicated that RNF31‐mediated ALYREF ubiquitylation could represent a potent target to reverse paclitaxel resistance in TNBC. Key points RNF31 facilitated ALYREF‐mediated PTX resistance in TNBC. RNF31 promoted ALYREF nuclear transport via IPO13 in response to PTX treatment, subsequently enhancing the export of mRNAs encoding PTX resistance‐related factors, including TUBB3, STMN1, and TAU. Blocking RNF31 trapped ALYREF in the cytoplasm and induced TNBC cell death upon PTX treatment. Inhibiting RNF31 activity re‐sensitized PTX‐resistant TNBC to PTX treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
- Department of Medicinal Laboratory, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Department of Radiation Oncology, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Scie…
- Department of Breast and Thyroid Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Breast Oncology Department, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
ORCID-Profile: Libing Song, Weidong Wei
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- China Postdoctoral Science Foundation
- China Postdoctoral Innovation Talent Support Program
- the Shenzhen Medical Research Funds
- the Guangdong Basic and Applied Basic Research Foundation-Guangdong-Shenzhen Joint Funds
Zitieren
APA
Huang, S., Shi, D., Dai, S., Jiang, X., Wang, R., Yang, M., Chen, B., Chen, X., Kong, L., He, L., Deng, P., Chen, X., Lin, C., Li, Y., Li, J., Song, L., Shi, Y., & Wei, W. (2025). RNF31 induces paclitaxel resistance by sustaining ALYREF cytoplasmic–nuclear shuttling in human triple‐negative breast cancer. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70203
Vancouver
Huang S, Shi D, Dai S, Jiang X, Wang R, Yang M, et al. RNF31 induces paclitaxel resistance by sustaining ALYREF cytoplasmic–nuclear shuttling in human triple‐negative breast cancer. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70203
BibTeX
@article{Huang2025,
author = {Huang, Shumei and Shi, Dongni and Dai, Shuqin and Jiang, Xingyu and Wang, Rui and Yang, Muwen and Chen, Boyu and Chen, Xuwei and Kong, Lingzhi and He, Lixin and Deng, Pinwei and Chen, Xiangfu and Lin, Chuyong and Li, Yue and Li, Jun and Song, Libing and Shi, Yawei and Wei, Weidong},
title = {RNF31 induces paclitaxel resistance by sustaining ALYREF cytoplasmic–nuclear shuttling in human triple‐negative breast cancer},
journal = {Clinical and Translational Medicine},
year = {2025},
doi = {10.1002/ctm2.70203}
}
EUVIMED